Can a sedative shield livers from transplant damage?

NCT ID NCT05031026

Ongoing Prevention Sponsor: Assiut University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug dexmedetomidine, given during liver transplant surgery, can protect the new liver and other organs from injury. Sixty adults receiving a living-donor liver transplant will be randomly assigned to receive either the drug or a placebo. The goal is to see if the drug reduces damage to blood vessel linings and lowers the risk of early liver failure or other complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexmedetomidine (also known as Precedex)
What this could lead to: If it works, this could point toward a way to protect the new liver and other organs from damage during transplant surgery.
What could go wrong: This is a small, early-phase study with only 60 participants, so results may not apply to everyone. The drug may not show a clear benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER TRANSPLANT; COMPLICATIONS

Contacts and locations

Locations

Assiut University

Asyut, 088, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.